Table 2.
Summary table with the description of the more used transcatheter technique/device of tricuspid valve intervention.
| Type of technique/device | Description | Strength | Limitation | Ongoing trials |
|---|---|---|---|---|
| Transcatheter tricuspid valve replacement | ||||
| Transcatheter tricuspid valve replacement: -Orthotopic implantation -Heterotopic implantation |
Implantation of a prosthetic valve in the tricuspid location or in the vena cava | Alternative option to repair techniques, mainly in patients with degeneration of previous tricuspid valve correction | Lack of experience | |
| Leaflets coaptation device | ||||
| TriClip (Abbott, Chicago, Illinois) | Edge-to-edge repair | Satisfactory reduction of tricuspid regurgitation and improvement in the functional class for patients not suitable for surgery | Lack of comprehensive data on eligible patients | |
| FORMA system (Edwards Lifesciences, Irvine, California) | Implantation of a balloon spacer anchored to right ventricle apex able to reduce regurgitant orifice area | Alternative options to edge-to-edge repair | Invasiveness of the device | |
| Suture annuloplasty devices | ||||
| - Trialign (Mitralign Inc, Tewksbury, MA) - Tricinch (4Tech Cardio Ltd., Galway, Ireland) |
System of anchors placed on the anterior and posterior segments of the tricuspid annulus | Reduction of tricuspid annulus diameter in patients not suitable for surgery | Lack of mid-term follow-up data | Safety and Feasibility of the Transcatheter Tricuspid Valve Repair System (Trialign) Trials Identifier: NCT04936802 |
| Prosthetic annuloplasty devices | ||||
| - Cardioband system (Edwards Lifesciences, Irvine, CA, USA) - Millipede IRIS (Millipede Inc., Santa Rosa, CA, USA) |
Transcatheter implantation of a prosthetic annulus | Reduction of tricuspid regurgitation in patients deemed inoperable | Lack of mid-term follow-up data | |